AN2 Therapeutics (ANTX) filed a shelf registration statement with US regulators on late Thursday for the potential sale of up to $300 million in securities, to be offered from time to time.
The filing covers common stock, preferred stock, debt securities, warrants and units.
The company said it will not receive any proceeds from the sale of common stock by selling securityholders.